TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
0.3617
-0.0363 (-9.12%)
Apr 16, 2025, 1:31 PM EDT - Market open
TransCode Therapeutics Employees
TransCode Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 9 or -47.37% compared to the previous year.
Employees
10
Change (1Y)
-9
Growth (1Y)
-47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,675,497
Market Cap
8.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 10 | -9 | -47.37% |
| Dec 31, 2022 | 19 | 10 | 111.11% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | 0 | - |
| Dec 31, 2019 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
RNAZ News
- 19 days ago - TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 - PRNewsWire
- 21 days ago - TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering - PRNewsWire
- 23 days ago - TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 4 weeks ago - TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial - PRNewsWire
- 7 weeks ago - TransCode Therapeutics, Inc. Announces Results of Special Meeting - PRNewsWire
- 2 months ago - TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - PRNewsWire
- 2 months ago - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - PRNewsWire
- 3 months ago - TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial - PRNewsWire